OXO-001 is under clinical development by Oxolife and currently in Phase II for Female Infertility. According to GlobalData, Phase II drugs for Female Infertility have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OXO-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OXO-001 is under development for promoting embryo implantation.
Oxolife, is a biotechnology company focused on treating female infertility. The company is headquartered in Spain.
For a complete picture of OXO-001’s drug-specific PTSR and LoA scores, buy the report here.